Hologic, Inc. (NASDAQ: HOLX), a leading provider of women's diagnostic imaging systems and digital radiographic applications, today announces the appointment of Georgia Hitzke as Vice President of Clinical Services. In this role, Ms. Hitzke will be responsible for domestic and international clinical services applications for all Hologic divisions. She will also interact with Hologic's other corporate officers to set strategic direction for the Company, and will be heavily involved in new product development, including Hologic's full-field digital mammography product line.
Prior to her appointment as Vice President, Ms. Hitzke served as Director of Clinical Services for Lorad, a division of Hologic involved in the development and manufacture of mammography and minimally invasive breast biopsy systems. She joined Lorad in this capacity in 1999, bringing with her more than 25 years of experience as a Radiology Manager for a large, multi- site radiology practice in Seattle, WA.
According to Jack W. Cumming, CEO and President of Hologic, "Hologic's acquisition of multiple companies over the past several years has created the need for focused leadership for the Company's clinical applications programs. It is our goal to assure best practices are employed and resources are utilized most efficiently and effectively across all operating divisions and practical, end-user considerations are incorporated into the development of all new products. With Ms. Hitzke's extensive background in radiological practices, her many years of management experience, and her in-depth knowledge of women's imaging issues, she is eminently qualified for this position."
As one of the first official acts in her new role, Ms. Hitzke has been empowered to create and chair a standing Advisory Committee on Women's Health composed of Hologic employees and external experts. The Committee's goal will be to provide recommendations for enhancing Hologic's focus on women's imaging issues, particularly in the areas of breast cancer and osteoporosis, and to ensure that current healthcare considerations in these areas are incorporated into strategic directives for the Company.
Commenting on her new role, Ms. Hitzke said, "My decision to join Lorad in 1999 was based on my personal experience with the excellence of Lorad's equipment and the dedication of the employees to providing improved methods for early detection of breast cancer. This commitment to improving the quality of women's healthcare is further evidenced by Hologic's forward- thinking decision to form the Advisory Committee on Women's Health. I look forward to the challenges of this new position and to using the contributions of the Advisory Committee to strengthen Hologic's foundation as the leading provider of medical imaging solutions for women's health."
Hologic, Inc. is dedicated to developing and delivering proprietary X-ray and ultrasound systems that incorporate direct-to-digital radiographic imaging technology for both women's health and general radiographic applications. Hologic's business divisions include Hologic Osteoporosis Assessment, a provider of premier bone densitometry systems, Hologic Radiographic Systems, encompassing general and digital radiography systems, and the wholly-owned subsidiaries: Direct Radiography Corp., a manufacturer of state-of-the-art proprietary flat panel technology called DirectRay®; Fluoroscan Imaging, a manufacturer of low intensity, real time X-ray imaging devices; and Lorad, specializing in innovative mammography and minimally invasive breast biopsy systems.
For more information, please visit http://www.hologic.com/. Forward Looking Disclaimers
This News Release contains forward-looking information that involves risks and uncertainties, including statements about Hologic's plans, objectives, expectations and intentions. Such statements include, without limitation, statements regarding the anticipated formation of the Advisory Committee and the benefits from that Committee and Ms. Hitzke's promotion. These forward- looking statements are subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those anticipated. Factors that could cause actual results to materially differ include, without limitation, Hologic's continuing losses and ability to fund those losses as well as other working capital requirements; Hologic's ability to predict accurately the demand for its products and to develop strategies to address its markets successfully; uncertainties inherent in the development of new products and the enhancement of existing products, including technical and regulatory risks, cost overruns and delays; the early stage of market development for digital X-ray products; risks relating to the Company's reliance on a single source of supply for some key components of its products; risks related to ongoing litigation; technical innovations that could render products marketed or under development by Hologic obsolete; competition; and reimbursement policies for the use of Hologic's products. Other factors that could adversely affect Hologic's business and prospects are described in Hologic's filings with the Securities and Exchange Commission. Hologic expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in the Company's expectations or any change in events, conditions or circumstances on which any such statement is based.
Contact: Glenn P. Muir Executive Vice President and CFO Hologic, Inc. (781) 999-7300 Marianne E. Ritchie Manager, Investor Relations Hologic, Inc. (781) 999-7300 MAKE YOUR OPINION COUNT - Click Here http://tbutton.prnewswire.com/prn/11690X17311838
SOURCE: Hologic, Inc.
Contact: Glenn P. Muir, Executive Vice President and CFO, or Marianne E. Ritchie, Manager, Investor Relations, of Hologic, Inc. +1-781-999-7300
Web site: http://www.hologic.com/